Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:CEO |
gptkb:Thomas_Oxley
|
| gptkbp:clinicalTrialPhase |
gptkb:Australia
gptkb:United_States |
| gptkbp:competitor |
gptkb:Neuralink
|
| gptkbp:focusesOn |
brain-computer interfaces
minimally invasive neural implants |
| gptkbp:foundedYear |
2016
|
| gptkbp:founder |
gptkb:Thomas_Oxley
|
| gptkbp:fundedBy |
gptkb:Elon_Musk
gptkb:Jeff_Bezos gptkb:Khosla_Ventures gptkb:ARCH_Venture_Partners gptkb:Gates_Frontier |
| gptkbp:headquartersLocation |
gptkb:Brooklyn,_New_York,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Synchron Inc.
|
| gptkbp:industry |
medical devices
neurotechnology |
| gptkbp:notableProduct |
gptkb:Stentrode
|
| gptkbp:regulatoryMilestone |
first FDA investigational device exemption for brain-computer interface implant
|
| gptkbp:website |
https://synchron.com
|
| gptkbp:bfsParent |
gptkb:Stentrode
|
| gptkbp:bfsLayer |
7
|